posted
on 2/9/2026
in
Press Releases
St. Anthony Regional Hospital has expanded its advanced cardiac care offerings with the successful implantation of the world’s smallest transvenous defibrillation lead. The procedure was performed by Dr. Suzanne Feigofsky, a cardiac electrophysiologist with Iowa Heart Center in Carroll, who has served the community since 2014.
The OmniaSecure™ defibrillation lead represents a significant advancement in cardiac device technology and is now available locally at St. Anthony Regional Hospital Surgical Center. St. Anthony is among the first hospitals in Iowa to offer this innovative lead, which is used in implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), including the Medtronic Cobalt™ and Crome™ systems.
At just 4.7 French in diameter, the OmniaSecure lead is the smallest transvenous defibrillation lead currently available. Traditional defibrillation leads are larger in diameter, which may increase the risk of complications such as venous occlusion or tricuspid valve regurgitation. The smaller profile of the OmniaSecure lead allows for more precise delivery and placement within the heart.
Defibrillation leads play a critical role in sensing heart rhythms and transmitting signals to implanted devices, which deliver therapy to correct or interrupt dangerous arrhythmias that can lead to sudden cardiac arrest (SCA). The OmniaSecure defibrillation lead is based on the Medtronic SelectSecure™ Model 3830 pacing lead, a technology that has provided safe and reliable therapy to patients for more than two decades.
In 2025, the U.S. Food and Drug Administration (FDA) approved the OmniaSecure™ defibrillation lead after clinical studies demonstrated its safety and effectiveness in patients at risk for sudden cardiac arrest. The lead is approved for use in both adults and adolescent pediatric patients ages 12 and older, including those with smaller anatomies.
FDA approval was supported by results from the LEADR Pivotal Trial, a global clinical study evaluating the safety and performance of the OmniaSecure lead when placed in traditional right ventricular locations. The trial demonstrated high defibrillation efficacy, low complication rates, and reliable performance, exceeding pre-specified performance thresholds.
“Being able to offer the OmniaSecure defibrillation lead at St. Anthony Regional Hospital means we can provide our patients with the most advanced, minimally invasive technology available,” said Dr. Suzanne Feigofsky. “Its smaller size allows for more precise placement in the heart, which may reduce the risk of complications while still delivering the lifesaving therapy patients need.”
Patients with heart rhythm disorders who would like to learn more about ICDs, CRT-Ds, and the leads that deliver lifesaving therapy are encouraged to speak with their physician. To learn more about the Iowa Heart Center in Carroll, click here.
Photos Courtesy of Medtronic.